Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Eden Research product receives key Spanish label extension

Published 24/06/2024, 07:44
Eden Research product receives key Spanish label extension

Proactive Investors - Eden Research PLC (LON:EDENE)'s flagship biofungicide, Mevalone, marketed as Araw in Spain, has received authorisation for expanded use in the country.

The product can now be used to treat powdery mildew on 22 new crops, botrytis cinerea on 20 new crops, rust disease on eight new crops, and sclerotinia on four new crops.

Included on the list are avocados, kiwis, mangos, cherries, chickpeas, green beans, asparagus, leeks, and artichokes. This expansion, achieved by Eden's partner Sipcam Iberia, makes Araw one of the most versatile biofungicides available for organic and conventional farming.

Araw has been effective against botrytis in grapes since its 2016 launch and gained popularity across a range of horticultural crops after a label expansion in 2021.

This approval will allow Spanish growers to protect their crops and meet high-quality export standards to the EU, UK, and other premium markets.

Eden anticipates that the broader market for Araw will boost revenues from 2025 onward, with further details to be provided as commercialisation commences.

Chief executive Sean Smith said: "Today's announcement is an excellent demonstration of our strategy to pursue growth opportunities through both new product introductions and with existing products by targeting new crop types and new disease targets.

"We are delighted to build on the success of our longstanding relationship with Sipcam. They have done an outstanding job of making the Iberian region an important and strong revenue-generating territory for the company.

"This label extension represents a significant additional growth opportunity for us. It not only includes numerous new crops and diseases, but it also includes a number of high-value crops that are particularly disease prone."

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.